EVENTIDE ASSET MANAGEMENT, LLC
Q1 2021 13F-HR Holdings
Net value change ($000)
+226,876
(3.5%)
New positions
21
Sold out positions
18
Turnover %
9.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Prometheus Biosciences, Inc. | 65,568 | NEW |
| ENTG | 61,420 | 823.3% |
| TSM | 50,780 | 1805.2% |
| CGEM | 49,025 | NEW |
| ZYMEWORKS INC | 44,147 | NEW |
| BBIO | 43,871 | NEW |
| EPIX | 43,404 | 164.0% |
| GNRC | 42,532 | 130.8% |
| DHI | 42,360 | 80.9% |
| MAX | 34,247 | 1422.8% |
Top Reduces (Value $000, Stocks/ETFs)
| SRPT | -106,854 | -67.3% |
| PRAX | -74,356 | -40.5% |
| ASND | -65,296 | -23.0% |
| ECL | -49,763 | -100.0% |
| CRWD | -49,636 | -23.4% |
| Eidos Therapeutics, Inc. | -41,766 | -100.0% |
| TTD | -38,879 | -17.9% |
| GW PHARMACEUTICALS PLC | -23,774 | -100.0% |
| Turning Point Therapeutics, Inc. | -23,271 | -32.8% |
| BFLY | -22,125 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,125
(0.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|